Skip Nav Destination
Developments in Ophthalmology
Pharmacology and Vitreoretinal Surgery
Edited by
S.Karger AG
Volume
44
Status:
Available
ISBN electronic:
978-3-8055-9030-3
ISBN print:
978-3-8055-9029-7
Book Series:
Developments in Ophthalmology
Publication date:
2009
Book Details
Since the advent of pars plana vitrectomy, immense technical advances in the treatment of retinal diseases have been made. However, some mechanically based limitations of vitreoretinal surgery may result in incomplete removal of the vitreous, especially at the vitreoretinal interface and at the vitreous base. Here, pharmacology can be of assistance. For instance, enzymes that cleave the vitreoretinal junction without damaging the retina or which induce liquefaction may be applied. Neuroprotective and antiproliferative agents may hold the promise of preserving neuronal function when the retina is detached or when proliferative vitreoretinopathy or proliferative diabetic retinopathy has developed. Earlier intervention is possible and can save visual function before the retinal cytoarchitecture is destroyed. Consequently, pharmacologic vitreolysis will change the current concepts of treating retinal and macular diseases. This volume is the first comprehensive up-date on pharmacology-assisted vitreoretinal surgery. Researchers in the fields of medical and surgical retina as well as retinal specialists and vitreoretinal surgeons in clinics will benefit from this topical summary.
Pharmacology and Vitreoretinal Surgery
Edited by: A. Gandorfer
https://doi.org/10.1159/isbn.978-3-8055-9030-3
ISBN (print): 978-3-8055-9029-7
ISBN (electronic): 978-3-8055-9030-3
Publisher: S.Karger AG
Published: 2009
Download citation file:
Digital Version
Pay-Per-View Access
$71.00
Print Version
Pharmacology and Vitreoretinal Surgery
$71.00
Table of Contents
-
1 - 6: Objective of Pharmacologic VitreolysisByArnd GandorferArnd GandorferVitreoretinal and Pathology Unit, University Eye Hospital Munich, Ludwig-Maximilians University, Munich, GermanySearch for other works by this author on:
-
7 - 19: Vitreous as a Substrate for VitreolysisByPaul N. BishopPaul N. BishopUniversity of Manchester and Manchester Biomedical Research Centre, Manchester Royal Eye Hospital, Manchester, UKSearch for other works by this author on:
-
20 - 25: Hyaluronidase for Pharmacologic VitreolysisByRaja Narayanan;Raja NarayananaSmt Kanuri Santhamma Vitreoretina Center, L.V. Prasad Eye Institute, Hyderabad, India;Search for other works by this author on:Baruch D. KuppermannBaruch D. KuppermannbUC Irvine Medical Center, Ophthalmology Clinic, Orange, Calif., USASearch for other works by this author on:
-
26 - 30: Microplasmin-Assisted VitrectomyByArnd GandorferArnd GandorferVitreoretinal and Pathology Unit, Augenklinik der Ludwig-Maximilians-Universität, Munich, GermanySearch for other works by this author on:
-
31 - 36: Pharmacologic Vitreodynamics and Molecular FluxByDavid T. Goldenberg;David T. GoldenbergaAssociated Retinal Consultants, Royal Oak, Mich., andSearch for other works by this author on:Michael T. TreseMichael T. TreseaAssociated Retinal Consultants, Royal Oak, Mich., andbEye Research Institute, Oakland University Rochester, Mich., USASearch for other works by this author on:
-
37 - 45: Glial Cell Changes of the Human Retina in Proliferative VitreoretinopathyByLouisa Wickham;Louisa WickhamVitreoretinal Unit, Moorfields Eye Hospital, London, UKSearch for other works by this author on:David G. CharterisDavid G. CharterisVitreoretinal Unit, Moorfields Eye Hospital, London, UKSearch for other works by this author on:
-
46 - 55: Alkylphosphocholines: A New Approach to Inhibit Cell Proliferation in Proliferative VitreoretinopathyByKirsten H. Eibl;Kirsten H. EiblaUniversity Eye Hospital, Ludwig-Maximilians-University, Munich, Germany;Search for other works by this author on:Steven K. Fisher;Steven K. FisherbNeuroscience Research Institute, University of California, Santa Barbara, Calif., USASearch for other works by this author on:Geoffrey P. LewisGeoffrey P. LewisbNeuroscience Research Institute, University of California, Santa Barbara, Calif., USASearch for other works by this author on:
-
56 - 68: Neuroprotection for Diabetic RetinopathyByHisanori Imai;Hisanori ImaiPenn State Hershey Eye Center and Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pa., USASearch for other works by this author on:Ravi S.J. Singh;Ravi S.J. SinghPenn State Hershey Eye Center and Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pa., USASearch for other works by this author on:Patrice E. Fort;Patrice E. FortPenn State Hershey Eye Center and Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pa., USASearch for other works by this author on:Thomas W. GardnerThomas W. GardnerPenn State Hershey Eye Center and Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pa., USASearch for other works by this author on:
-
69 - 81: VEGF Inhibitors and Vitrectomy for Diabetic VitreoretinopathyByCarlos E. Cury, Jr;Carlos E. Cury, JraSports Genetics Laboratory, St Petersburg Research Institute of Physical Culture, St. Petersburg, andSearch for other works by this author on:Eduardo B. Rodrigues;Eduardo B. RodriguesaSports Genetics Laboratory, St Petersburg Research Institute of Physical Culture, St. Petersburg, andSearch for other works by this author on:Carsten H. Meyer;Carsten H. MeyerbLaboratory of Muscle Performance, SRC RF I nstitute for Biomedical Problems of the Russian Academy of Sciences, Moscow, RussiaSearch for other works by this author on:Michel E. FarahMichel E. FarahaSports Genetics Laboratory, St Petersburg Research Institute of Physical Culture, St. Petersburg, andSearch for other works by this author on:
-
82 - 88: Tissue Plasminogen Activator-Assisted Vitrectomy: Surgical Drainage of Submacular HemorrhageByMotohiro Kamei;Motohiro KameiDepartment of Ophthalmology, Osaka University Graduate School of Medicine, Suita, JapanSearch for other works by this author on:Yasuo TanoYasuo TanoDepartment of Ophthalmology, Osaka University Graduate School of Medicine, Suita, JapanSearch for other works by this author on:
-
89 - 97: Anti-Angiogenic Therapy in the Management of Retinopathy of PrematurityByKimberly A. DrenserKimberly A. DrenserAssociated Retinal Consultants, Royal Oak, Mich., and Eye Research Institute, Oakland University, Rochester, Mich., USASearch for other works by this author on:
